IQVIA Adopts Veeva Software to Standardize Clinical Trials
The extended partnership enables one-day system configuration for global clinical research trials.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust that the increasing use of AI in clinical trials is safe for patients?
IQVIA has officially adopted a suite of clinical trial software from Veeva as its new enterprise standard to streamline development processes. The expanded partnership leverages integrated applications for trial management and document handling across IQVIA’s global clinical studies.
Why it matters
This move aims to reduce complexity in trial execution by standardizing the technical architecture used by one of the largest clinical research organizations in the industry. It reflects a broader push to automate trial configuration as demand for faster data processing grows among drug developers.
The adoption includes Veeva eTMF, CTMS, Study Startup, and Site Connect applications to manage trial data. Veeva’s recently introduced Study Builder technology allows for the configuration of clinical systems in one day, replacing longer manual setup periods.
The players
IQVIA
A global provider of advanced analytics, technology solutions, and contract research services for the life sciences industry.
Veeva
A cloud-computing company specializing in industry-specific software for the global life sciences sector, focusing on data management and trial automation.
The details
The integration utilizes a centralized software stack to automate workflows across clinical development. The Veeva Study Builder technology functions by standardizing clinical system configuration, minimizing the time required to initiate new study protocols. These tools facilitate standardized data exchange and document management, replacing siloed systems that previously complicated trial oversight for research organizations.
Timeline
2025: IQVIA and Veeva established their initial partnership.
September 2026: Industry analysis was published regarding current AI adoption in clinical trials.
October 2026: IQVIA and Veeva extended their clinical trial technology partnership.
The Tech Race
This partnership marks a significant consolidation of enterprise software stacks within the contract research market. It positions IQVIA to accelerate its adoption of AI-driven trial tools relative to competitors currently managing trials through fragmented or legacy systems.
The transition to this unified software stack is set to impact global clinical research operations by reducing the setup time for trial systems to a single day. Drug developers and research teams working with IQVIA can expect these standardized tools to be phased into ongoing and future clinical development workflows.
The takeaway
The move underscores a shift toward standardized software platforms to support increasingly complex clinical trial requirements. Observers should track whether this one-day system configuration capability leads to measurable improvements in total trial duration across IQVIA’s portfolio.
Further reading
For broader trends in research infrastructure, see our analysis on Biotech.
Source note: This article includes information reported by BioXconomy.
Live Poll
Do you trust that the increasing use of AI in clinical trials is safe for patients?
